2025 ASCO Annual Meeting
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3, 2025, online and on-site at McCormick Place in Chicago, Illinois. It featured over 5,000 abstracts and more than 200 sessions of interactive content showcasing the latest in oncology clinical research.
Advertisement
Elranatamab shows durable responses and manageable safety in heavily pretreated US patients with myeloma.
Blood clot risk tools may fall short for myeloma patients—study shows aspirin alone might not be enough.
Belantamab may return for RRMM after DREAMM trials show benefit, despite ongoing concerns about eye toxicity.
The three-arm study enrolled patients with disease refractory to prior carfilzomib, daratumumab, or pomalidomide therapy.
At 5 years, 33% of patients with myeloma receiving cilta-cel in the CARTITUDE-1 trial are alive and disease free.
AI is revolutionizing oncology with faster analysis, better predictions, and more personalized cancer care.
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
Peripheral blood samples were analyzed within a phase 2 trial of this bispecific antibody as 1L treatment for FL and MZL.
Ibrutinib plus venetoclax shows strong CR rates and durable remissions in older and younger MCL patients with TP53 mutations.
Zanubrutinib and venetoclax show deep and lasting responses in frontline CLL and SLL including those with del 17p or TP53.
A fixed duration regimen of the combination was compared with a regimen guided by measurable residual disease.
Of 128 efficacy-evaluable patients, the ORR was 80.5% and the CR rate was 74.2% at a median follow-up of 28.3 months.
Azacitidine plus valproic acid is a safe and feasible maintenance regimen for patients with high-risk AML and MDS after HSCT.
Dr. Andorsky discusses CML dose escalation, treatment discontinuation, and unmet needs in leukemia care.
Frontline luspatercept demonstrates superior efficacy compared with ESAs in patients with lower-risk MDS.
100% MRD-negative CR in Ph+ ALL? Dr. Catherine Lai recaps standout abstracts from an ASCO rapid oral session.
The median progression-free survival was 33.2 months in the BVd arm, compared with 11.1 months in the DVd arm.
Naval Daver, MD, presented on the efficacy and safety of bexmarilimab plus standard-of-care azacitidine for MDS at ASCO 2025.
Dr. Tam reviews 5-year data from SEQUOIA showing strong efficacy of zanubrutinib in older CLL patients with 17p deletion.
Belantamab mafodotin plus pomalidomide-dexamethasone showed greater efficacy to pomalidomide-bortezomib-dexamethasone.
Gecacitinib improved spleen volume, symptoms, and anemia in JAK inhibitor–naive MF, regardless of baseline anemia severity.
Cilta-cel improves PFS and OS in len-refractory MM across subgroups, including high-risk cytogenetics, per CARTITUDE-4.
Zanubrutinib shows durable efficacy and safety in high-risk CLL/SLL, regardless of 17p deletion, per 5-year SEQUOIA data.
IME shows strong efficacy in LR-MDS, offering transfusion independence in heavily pretreated, ESA-ineligible patients.
EPCOR shows durable remission and survival at 2 years in R/R LBCL, with promising safety from fixed-duration treatment.
A phase 2/3 trial is evaluating zilovertamab vedotin plus rituximab and gemcitabine-oxaliplatin in relapsed/refractory DLBCL.
Asciminib shows safety and efficacy as a 2nd-line treatment in CML-CP without T315I, per interim phase 2 ASC2ESCALATE results
Zilovertamab vedotin plus R-GemOx shows promise in R/R DLBCL, with RP2D set at 1.75 mg/kg per WaveLINE-003 phase 2/3 trial.
Coverage of the 2025 ASCO Annual Meeting from Blood Cancers Today, a Formedics property.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.